DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 6, 2025

Triple-negative breast cancer (TNBC) is an aggressive subtype of characterized by the lack estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2). Chemotherapy remains primary treatment option, yet TNBC frequently develops resistance, leading to relapse metastasis. Emerging evidence highlights potential combining DNA methylation inhibitors with immune checkpoint (ICIs). contributes escape silencing immune-regulatory genes, thereby reducing tumor's visibility cells. Reversing this epigenetic modification can reinvigorate surveillance enhance efficacy immunotherapies. This review discusses role in progression evasion, focusing on recent advances combination therapies involving ICIs. We discuss underlying mechanisms that enable these therapeutic synergies, preclinical clinical supporting approach, challenges posed tumor heterogeneity, drug toxicity. Finally, we explore for personalized strategies incorporating multi-omics data optimize outcomes. The integration immunotherapy offers a promising avenue improving survival patients.

Language: Английский

Chen’s peiyuan tang and premature ovarian failure: unveiling the mechanisms through network pharmacology

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 29, 2024

Chen's Peiyuan Tang (CSPYT) is a compound herbal formula that has shown the potential to enhance ovarian function and reduce autophagy in granulosa cells, which plays crucial role follicular development maturation. The application of Chinese medicine offers promising alternative traditional hormone replacement therapy (HRT).

Language: Английский